(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israel reports second missile fire from Yemen since start of Iran war - 2Hoist Your Style: Famous Hairdos for Ladies
- 3No injuries after blast at pro-Israel centre in the Netherlands
- 4Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
- 5Turkey, Egypt, Qatar discuss second phase of Gaza ceasefire deal
- Genetic study identifies earliest-known dog, dating to 15,800 years ago
- Cyprus: War-related tourism concerns and climate change efforts
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- Vote In favor of Your Favored Kind Of Organic product
- CRP Subsea secures contract for Vattenfall’s Nordlicht I cable systems
- We may have one thing in common with jellyfish, new research finds
- RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- How to track NASA’s Artemis II and Orion’s journey to the moon
